Business news

    Proteomics (ASX:PIQ) resubmits kidney test for application for Australian MBS

    Article Image

    Proteomics International Laboratories (ASX:PIQ) has resubmitted an application to have the PromarkerD predictive test for diabetic kidney disease included in the Australian Medicare Benefits Schedule (MBS).

    The MSAC (Medical Services Advisory Committee) denied their initial application due to concerns about the cost of the test and lack of data on how use of PromarkerD would change clinical practice.

    Despite this, MSAC acknowledged that in the long term, its introduction could save the healthcare system money.

    Proteomics says it's confident it can provide the necessary information to address these items and has a comprehensive body of evidence to support its test which has been endorsed by key bodies in the USA and UK.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa